Drug Database
LA

lanbotulinumtoxinA (HengLi / Lantox / lanbotulinumtoxinA)

✓ Approved

Lanzhou Institute · therapeutic agent

What is lanbotulinumtoxinA?

lanbotulinumtoxinA is a therapeutic agent developed by Lanzhou Institute. It is approved for therapeutic indications via injectable (others) or intradermal injection or intramuscular (im) injection.

Drug Profile

Brand NamesHengLi, Lantox, lanbotulinumtoxinA
CompanyLanzhou Institute
RouteInjectable (Others), Intradermal Injection, Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Lanzhou Institute

Therapeutic Indications

lanbotulinumtoxinA is developed for 11 unique indications across 7 therapeutic areas.

Therapeutic AreaConditionPhase
Eye disordersBlepharospasm✓ Approved
Musculoskeletal and connective tissue disordersMuscle spasms✓ Approved
Skin and subcutaneous tissue disordersSkin wrinkling✓ Approved
Eye disordersStrabismus✓ Approved
Eye disordersBinocular eye movement disorder✓ Approved

+6 more indications available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedJournal of neural transmission (Vienna, Austria : 1996)2026-06-18

Comparative efficacy and safety of botulinum neurotoxin type A in blepharospasm and hemifacial spasm: a systematic review and Bayesian network meta-analysis.

Kühn Zsófia Z, Scheibl Rabán R, Schnider Peter P

While botulinum neurotoxin type A (BoNT-A) has demonstrated efficacy in the treatment of blepharospasm and hemifacial spasm, comparative efficacy and safety of different BoNT-A formulations remain uncertain. We conducted a systematic review and network meta-analysis with random-effects Bayesian models of randomized controlled trials comparing BoNT-A preparations with each other or with placebo. Separate networks were constructed for duration of clinical effect, analyzed as mean differences (MD), and ptosis, analyzed as odds ratios (ORs). The network included 13 randomized controlled trials with 870 participants contributing to duration outcomes and 964 participants to ptosis outcomes. All BoNT-A preparations demonstrated a significantly longer duration of clinical effect compared with placebo in a combined blepharospasm and hemifacial spasm population. No clinically meaningful differences in duration were observed between active preparations. AbobotulinumtoxinA (Abo/BoNT-A), onabotulinumtoxinA (Ona/BoNT-A), incobotulinumtoxinA (Inco/BoNT-A) and lanbotulinumtoxinA (Lan/BoNT-A) were associated with significantly higher odds of ptosis compared with placebo. Abo/BoNT-A, which was generally administered at higher dose ratios in the included studies, showed higher odds of ptosis than Ona/BoNT-A, although estimates were imprecise with wide credible intervals. In the dose-level network, higher-dose BoNT-A was associated with a greater risk of ptosis than lower-dose BoNT-A. The available evidence suggests that BoNT-A formulations have comparable efficacy in the combined blepharospasm and hemifacial spasm population. Differences in ptosis risk may reflect differences in dosing strategies rather than intrinsic differences between BoNT-A formulations. The review protocol was registered in PROSPERO (CRD420261299121).

PMID 42313173
Read full article →
PubMedToxins2024-11-26

Botulinum Toxin Type A for Trigeminal Neuralgia: A Comprehensive Literature Review.

Tereshko Yan Y, Dal Bello Simone S, Lettieri Christian C, Belgrado Enrico E et al.

Trigeminal neuralgia is a neuropathic pain syndrome responsive to botulinum toxin type A therapy. This review had the goal of analyzing the different studies published from 2002 to January 2024 to better define the techniques and the types of botulinum toxin type A used, the doses, the injection routes, and the different populations of trigeminal neuralgia patients treated. We considered only articles in which the therapy was administered to humans to treat trigeminal neuralgia. Case reports, case series, open-label, retrospective, and RCT studies were considered. The research was conducted on MEDLINE and the keywords included (trigeminal neuralgia) and (botulinum). Thirty-five articles were considered suitable for this review. Botulinum toxin type A was shown to be an effective therapy for TN pain in all the articles analyzed, albeit there is a lack of standardization in methods and outcomes. The techniques, the doses, and the injection approaches were very heterogeneous among the studies. Only two botulinum toxin type A formulations have been used in this setting: onabotulinumtoxinA and lanbotulinumtoxinA. There were 300 patients treated with onabotulinumtoxinA and 760 treated with lanbotulinumtoxinA overall (in 42 patients, the formulation was not specified). The distinction between etiological and clinical types of TN has been made by only a small portion of the studies. The main adverse event was transient facial asymmetry. Botulinum toxin type A is indeed a promising therapy that is clearly effective for trigeminal neuralgia. OnabotulinumtoxinA is the most common formulation used in Western countries; however, the meager sample of TN patients treated, and the lack of standardization are not sufficient for this therapy to be approved by the FDA or EMA. Indeed, more studies with standardized methods and larger samples are needed for this purpose.

PMID 39591255
Read full article →
PubMedJournal of cosmetic dermatology2022-05-24

Ultrasonographic observation of the masseter muscle after injection of different botulinum toxin type A.

Li Zhujun Z, Li Zirong Z, Li Yunzhu Y, Dong Ruijia R et al.

Botulinum toxin type A (BoNT-A) injection is a popular cosmetic procedure in East Asian countries, and there are multiple types of toxins on the market. Whether different toxin types induce different changes in the masseter has not been studied. We aimed to investigate and compare the changes induced by injection of different types of BoNT-A in the masseter. Upon retrospective review of clinical records and routine ultrasound examination results of patients who underwent BoNT-A injection, four groups were set for comparison: unapproved toxin, OnabotulinumtoxinA, LanbotulinumtoxinA, and non-injected. Clinical records and ultrasound images were collected. Ultrasound images were taken in both horizontal and coronal planes. Elasticity of the masseter muscle was also investigated by measuring the surface wave speed. A total of 24 patients were included (six patients per group). All patients were young females. For the non-injected group, the deep inferior tendon was clear and the muscle bundles were arranged, with little fibrous content. Patients who received unapproved toxin injection showed highly disarranged muscle and fiber bundles, with much fiber content present. The changes in OnabotulinumtoxinA and LanbotulinumtoxinA groups were in between those in the non-injected and unapproved toxin groups. Muscle rigidity was the highest in the unapproved toxin group, and generally higher in injected groups compared with the non-injected group. Different types of BoNT-A may induce different changes in the masseter.

PMID 35599608
Read full article →
PubMedToxins2021-06-03

Lantox-The Chinese Botulinum Toxin Drug-Complete English Bibliography and Comprehensive Formalised Literature Review.

Dressler Dirk D, Pan Lizhen L, Su Junhui J, Teng Fei F et al.

In 1997, lanbotulinumtoxinA (LAN) was introduced in China. It is now available in Asia, Latin America and Eastern Europe under various brand names including Hengli®, Lantox®, Prosigne®, Lanzox®, Redux®, Liftox®, HBTX-A and CBTX-A. The literature on LAN is mostly published in Chinese language, restricting its international accessibility. We, therefore, wanted to generate a complete English bibliography of all LAN publications and then use it for a comprehensive formalised literature review. Altogether, 379 LAN publications (322 in Chinese and 57 in English) were retrieved from PubMed and Science and Technology Paper Citation Database. Indications covered are motor (257), glandular (16), pain (32) and aesthetics (48). Topics are neurological (250), aesthetic (48), paediatric (38), ophthalmological (18), urological (9), methodological (6), gastroenterological (5), ear, nose and throat (4) and surgical (1). Seventy-one publications are randomised controlled trials, forty-one publications are interventional studies and observational studies, fifteen publications are case studies, eighteen publications are reviews, and two publications are guidelines. LAN publications cover all relevant topics of BT therapy throughout a period of more than 20 years. This constitutes a publication basis resembling those of other BT drugs. None of the LAN publications presents data contradictory to those generated with other BT type-A drugs. LAN seems to have a similar efficacy and safety features when compared to onabotulinumtoxinA using a 1:1 LAN- onabotulinumtoxinA conversion ratio. Large controlled multicentre studies will become necessary for LAN's registrations in Europe and North America.

PMID 34067301
Read full article →
PubMedJournal of neural transmission (Vienna, Austria : 1996)2019-11-11

Comparing lanbotulinumtoxinA (Hengli®) with onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in the mouse hemidiaphragm assay.

Pan Lizhen L, Bigalke Hans H, Kopp Bruno B, Jin Lingjing L et al.

LanbotulinumtoxinA (LAN) is manufactured and registered in China since 1994. Despite its widespread use in China and its increasing use in other Asian countries and in South America, it is not yet well known elsewhere. We wanted to compare its potency labelling using the mouse diaphragm assay (MDA), an isolated muscle model for botulinum toxin (BT) potency measurements, which is superior to clinical tests and which was recently refined as an alternative batch release assay for BT manufacturing. We also wanted to estimate LAN manufacturing quality by testing its inter-batch potency consistency. Potencies of 20, 60 and 100 MU of LAN, onabotulinumtoxinA (ONA) and incobotulinumtoxinA (INCO) were measured by the inversely related paresis time (PT) in the MDA. The PT (M ± SD) of all doses of LAN, ONA and INCO was 90.4 ± 27.0 min, 114.9 ± 46.5 min and 94.3 ± 29.9 min, respectively. Statistical analysis demonstrated indistinguishable potency labelling of LAN and INCO, but revealed a slightly lower potency of ONA compared to LAN and INCO. PT of LAN batch 1 and LAN batch 2 was 86.9 ± 21.2 min and 94.0 ± 32.8 min, respectively (no statistically significant difference), suggesting an adequate LAN manufacturing consistency. The MDA is an appropriate instrument for potency testing of BT drugs, including new ones currently under development. Our results allow comparing therapeutic effects, adverse effects and economics of LAN, ONA and INCO. They also suggest adequate manufacturing consistency of LAN.

PMID 31707463
Read full article →
PubMedDrug design, development and therapy2017-07-20

Comparison of neurotoxic potency between a novel chinbotulinumtoxinA with onabotulinumtoxinA, incobotulinumtoxinA and lanbotulinumtoxinA in rats.

Feng Ya Y, Liu Wuchao W, Pan Lizhen L, Jiang Cong C et al.

Four botulinumtoxin type A (BoNT/A) products, onabotulinumtoxinA (A/Ona), incobotulinumtoxinA (A/Inco), lanbotulinumtoxinA (A/Lan) and chinbotulinumtoxinA (A/Chin), are applied in the present study, among which A/Chin is newly produced. We aimed to compare the neurotoxic potency of these toxins by the gauge of muscle strength reduction. Furthermore, potential molecular and cellular mechanisms were also explored. According to our data, muscle strengths in the four toxin groups were all significantly decreased after injection for 1 week. A/Chin achieved the most obvious reduction in muscle strength as compared to the other three products at the dose of 0.5 U. However, there was no difference between the four toxins when increased to 2 U. As the toxins wore off, muscle strength recovered to basal level 12 weeks postinjection. We further measured the expression levels of key factors involved in neuromuscular junction stabilization and muscle genesis. Our results showed that nicotinic acetylcholine receptor, myogenic regulatory factors and muscle-specific receptor tyrosine kinase were all significantly upregulated upon BoNT/A treatment. Consistent with the result of muscle strength, A/Chin had the most obvious induction of gene expression. Moreover, we also found local inflammation response following BoNT/A injection. Owing to lack of complexing proteins, both A/Inco and A/Chin stimulated relatively lighter inflammation compared to that of A/Ona and A/Lan groups. In conclusion, our study provided evidence for the efficacy of the novel A/Chin and its similar functional mode to that of A/Ona, A/Inco and A/Lan. In addition, A/Chin has superiority in inducing muscle paralysis and inflammation stimulation, which may indicate faster onset and longer duration of this novel A/Chin.

PMID 28721012
Read full article →

+2 more articles available with a free account

Sign up free to view all articles →

Ask about lanbotulinumtoxinA